| ||||||||||||||||||||||
| Mice that are homozygous for the targeted allele and hemizygous for the transgene express all six isoforms (including both 3R and 4R forms) of human microtubule-associated protein tau (MAPT). These mutant mice may be useful in studies examining the relationship between human MAPT and Alzheimer's disease pathogenesis | ||||||||||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
Strain Information
Former Names B6.Cg-Mapttm1(GFP)Klt Tg(MAPT)8cPdav/J (Changed: 14-APR-06 ) Type Congenic; Mutant Strain; Targeted Mutation; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System See Colony Maintenance under the Health & husbandry tab (Female x Male) 09-DEC-06 Species laboratory mouse Generation N9+1F7 (31-DEC-08)
Generation DefinitionsDonating Investigator Karen Duff, Nathan Kline Institute Donating Investigator Peter Davies, Albert Einstein College of Medicine Description
Mice that are homozygous for the targeted allele and hemizygous for the transgene are viable and fertile. Although no endogenous mouse MAPT is detected, all six isoforms (including both 3R and 4R forms) of human MAPT are expressed. Hyperphosphorylated MAPT is detected in cell bodies and dendrites by three months of age. Paired helical filaments of aggregated insoluble MAPT can be isolated from brain tissue as early as two months of age. These mutant mice may be useful in studies examining the relationship between human MAPT and Alzheimer's disease pathogenesisIn an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
Development
Double mutant mice were generated by crossing transgenic mice (mouse line 8C) with Mapt targeted mutant mice. The targeted mutant allele was created by inserting EGFP coding sequence into the first Mapt exon, disrupting expression of the Mapt gene and producing a cytoplasmic EGFP protein fused to the first 31 MAPT amino acids (see Stock Number 004779). The transgenic allele consists of a PAC insert of 200-250 kb that includes the coding sequence, intronic regions and regulatory elements of the human MAPT gene. The targeted allele was created in 129S4/SvJae-derived J1 embryonic stem cells which were subsequently injected into C57BL/6 blastocysts. The transgenic allele was generated in embryos derived from a cross between Swiss Webster females and B6D2F1 males. Mice containing both alleles were crossed to C57BL/6 mice for nine generations by the donating investigator. Upon arrival at The Jackson Laboratory, the mice were crossed once more to C57BL/6 (N10). Offspring were mated to generate mice that are homozygous at the targeted mutant allele.
Control Information
| Control | ||
|---|---|---|
| See control note: | Mice from the colony that are homozygous for the targeted mutation and noncarrier for the transgene should be considered for use as controls. The most appropriate control animal will depend on the nature of the experiment. | |
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Alzheimer's Disease Models
View Alzheimer's Disease Models (108 strains)
004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 004779 STOCK Mapttm1(EGFP)Klt/J
004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
007251 B6.129-Mapttm1Hnd/J 018282 B6.Cg-Mapttm1(Mecp2)Jae/LimmJ 012639 B6;129S4-Mapttm3(HDAC2)Jae/J
Additional Web Information
Fluorescent Proteins/lacZ Systems
Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
Phenotype
Phenotype Information
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Alzheimer Disease; AD
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Frontotemporal Dementia; FTD (MAPT)
Parkinson Disease, Late-Onset; PD (MAPT)
Parkinson-Dementia Syndrome (MAPT)
Pick Disease of Brain (MAPT)
Supranuclear Palsy, Progressive, 1; PSNP1 (MAPT)
assigned by genotype
Mapttm1(EGFP)Klt/Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/0
B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
- behavior/neurological phenotype
- abnormal spatial learning
- 6 month old mutants exhibit slower visuospatial learning than control mice (MGI Ref ID J:172426)
- in the visuospatial re-learning test performed at 7, 8, 9, and 15 months of age, mutants exhibit a decrease in the speed of re-learning the task compared to controls (MGI Ref ID J:172426)
- however, mutants perform better than Tg(APPswe,PSEN1dE9)85Dbo mice on the visuospatial re-learning test at 9 and 18 months of age (MGI Ref ID J:172426)
- taste/olfaction phenotype
- *normal* taste/olfaction phenotype
- mutants do not exhibit Alzheimer's disease-related impairment in olfactory performance in tests based on an operant conditioning procedure and in tests based on a habituation/dishabituation procedure (MGI Ref ID J:172426)
- nervous system phenotype
- neurofibrillary tangles (MGI Ref ID J:172426)
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Mapttm1(EGFP)Klt/Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/?
involves: 129S4/SvJae * C57BL/6 * Swiss Webster
- nervous system phenotype
- abnormal neuron morphology
- cells in the cortex and hippocampus appear irregularly shaped, often with distorted processes in 13 month old mice (MGI Ref ID J:84638)
- tau protein deposits
- phosphorylated tau accumulates in neuronal cell bodies and dendrites of the hippocampus and neocortex as early as 3 months of age (MGI Ref ID J:84638)
- in particular, accumulations occur in entorhinal cortex, ventromedial hypothalamus, medial septum and the nucleus of the horizontal limb of the diagonal band (MGI Ref ID J:84638)
- increase in tau phosphorylation occurs at serine 202, threonine 231 and serine 235 as determined by immunoblot (MGI Ref ID J:84638)
- tau aggregates in the proximal dendrites have an average width of 15 nm and are not densely packed (MGI Ref ID J:84638)
- insoluble tau is present in both 2 and 9 month old mice (MGI Ref ID J:84638)
- paired helical filaments are observed in 9, 12 and 14 month old mice (MGI Ref ID J:84638)
- hematopoietic system phenotype
- abnormal spleen B cell follicle morphology
- splenic white pulp contains follicles that are larger and more irregular in shape than normal follicles and are often fused with adjacent follicles (MGI Ref ID J:174270)
- abnormal spleen red pulp morphology
- splenic red pulp is largely obliterated (MGI Ref ID J:174270)
- immune system phenotype
- abnormal spleen B cell follicle morphology
- splenic white pulp contains follicles that are larger and more irregular in shape than normal follicles and are often fused with adjacent follicles (MGI Ref ID J:174270)
- abnormal spleen red pulp morphology
- splenic red pulp is largely obliterated (MGI Ref ID J:174270)
- other phenotype
- amyloidosis
- some mutants older than 18 months exhibit amyloid deposits in the spleen, kidneys, liver, ovary and/or heart (MGI Ref ID J:174270)
- amyloid is deposited concentrically in the perifollicular sheath, partly or completely encircling the follicles in the spleen (MGI Ref ID J:174270)
- in the liver, amyloid deposit is in the walls of sinusoids or central veins (MGI Ref ID J:174270)
- in the kidney, amyloid deposits are seen in the glomeruli (MGI Ref ID J:174270)
- amyloid deposits in the heart are not composed of amyloid-beta peptide, but rather amyloid A (MGI Ref ID J:174270)
- renal/urinary system phenotype
- abnormal renal glomerulus morphology
- kidney glomeruli are dilated probably due to obstruction from the amyloid in the lumen or walls of medullary tubules especially in the papilla (MGI Ref ID J:174270)
- tumorigenesis
- increased lymphoma incidence
- follicular lymphoma
- splenic architecture is replaced by proliferated immature mononuclear cells arranged in follicular aggregates indicating follicular lymphoma (MGI Ref ID J:174270)
This mouse can be used to support research in many areas including:
GFP relatedNeurobiology Research
Alzheimer's Disease
Research Tools
Fluorescent Proteins
Genetics Research
Tissue/Cell Markers
Tissue/Cell Markers: neurons
Neurobiology Research
cell marker
MAPT relatedResearch Tools
Fluorescent Proteins
Mapttm1(EGFP)Klt relatedNeurobiology Research
Alzheimer's Disease
Parkinson's Disease
Tg(MAPT)8cPdav relatedNeurobiology Research
Alzheimer's Disease
Tau (Mapt) mutants
Tau (Mapt) mutants
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Mapttm1(EGFP)Klt | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Kerry Lee Tucker | ||
| Allele Type | Targeted (Reporter) | ||
| Common Name(s) | Mapttm1(GFP)Klt; tau ko; tauGFP; | ||
| Mutation Made By | Dr. Kerry Tucker, Ruprecht Karls University of Heidelberg | ||
| Strain of Origin | 129S4/SvJae | ||
| ES Cell Line Name | J1 | ||
| ES Cell Line Strain | 129S4/SvJae | ||
| Site of Expression | GFP signal is detected beginning a embryonic day 9 in the trigeminal ganglion and throughout the developing central nervous system by embryonic day 10.75. GFP expression persists in adults and closely resembles the expression of neuron specific beta-tubulin III. | ||
| Expressed Gene | GFP, Green Fluorescent Protein, jellyfish | ||
| Green Fluorescent Protein (GFP), derived from the jellyfish Aequorea victoria, is a versatile reporter molecule which has found use in many biological applications. In some constructs the original molecule has been modified in order to enhance its fluorescence intensity (EGFP, enhanced GFP). When utilized in a transgenic construct, tissue expressing sufficient amounts of GFP will fluoresce when exposed to a 488 nm light source. | |||
| Molecular Note | Exon 1 was disrupted by the insertion of a cassette encoding EGFP and neo. Fusion protein including GFP was detected by Western blot analysis of homozygous mutant brain lysates. Fluorescent illumination indicated that expression of the reporter gene was similar to that of the endogenous gene. [MGI Ref ID J:66561] | ||
| Gene Symbol and Name | Mapt, microtubule-associated protein tau | ||
| Chromosome | 11 | ||
| Gene Common Name(s) | AI413597; AW045860; DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; Mtapt; PPND; RNPTAU; TAU; Tau; expressed sequence AI413597; expressed sequence AW045860; pTau; | ||
| Allele Symbol | Tg(MAPT)8cPdav | ||
| Allele Name | transgene insertion 8c, Peter Davies | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | 8c; hTau; | ||
| Mutation Made By | Peter Davies, Albert Einstein College of Medicine | ||
| Strain of Origin | Swiss Webster x (C57BL/6 x DBA)F1 | ||
| Site of Expression | Neurons: EGFP signal observed at 9.0 dpc (days post-coitum) in the trilgeminal ganglion. At 10.75 dpc. EGFP was seen throughout the developing nervous system. | ||
| Expressed Gene | MAPT, microtubule-associated protein tau, human | ||
| Promoter | MAPT, microtubule-associated protein tau, human | ||
| General Note | Mice that are homozygous for the Mapttm1(GFP)Klt allele and hemizygous for the transgene are viable and fertile. Although no endogenous mouse MAPT is detected, all six isoforms (including both 3R and 4R forms) of human MAPT are expressed. Hyperphosphorylated MAPT is detected in cell bodies and dendrites by 3 months of age. Paired helical filaments of aggregated insoluble MAPT can be isolated from brain tissue as early as 2months of age. | ||
| Molecular Note | The transgene contains the coding sequence, intronic regions, and regulatory elements of the human microtubule-associated protein tau (MAPT) gene. [MGI Ref ID J:85952] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Generic Human PSEN1 cDNA Multiplex1, Melt Curve Analysis
Generic Mouse App cDNA Multiplex1, Melt Curve Analysis
Generic Tg(APP) Melt Curve Analysis,MELT
Generic Tg(APP) Melt Curve Analysis, Melt Curve Analysis
Tg(PDGFB-APP) MCA, Melt Curve Analysis
Mapttm1(EGFP)Klt, Melt Curve Analysis
Mapttm1(EGFP)Klt, Standard PCR
Tg(MAPT)8cPdav, Melt Curve Analysis
Tg(MAPT)8cPdav, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References provided by MGI
Selected Reference(s)
Andorfer C; Kress Y; Espinoza M; de Silva R; Tucker KL; Barde YA; Duff K; Davies P. 2003. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86(3):582-90. [PubMed: 12859672] [MGI Ref ID J:84638]
Additional References
Mapttm1(EGFP)Klt relatedTg(MAPT)8cPdav relatedAcker CM; Forest SK; Zinkowski R; Davies P; d'Abramo C. 2013. Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging 34(1):338-50. [PubMed: 22727277] [MGI Ref ID J:191604]
Ando K; Leroy K; Heraud C; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP. 2011. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178(2):803-16. [PubMed: 21281813] [MGI Ref ID J:169074]
Andorfer C; Acker CM; Kress Y; Hof PR; Duff K; Davies P. 2005. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25(22):5446-54. [PubMed: 15930395] [MGI Ref ID J:98717]
Boutajangout A; Quartermain D; Sigurdsson EM. 2010. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49):16559-66. [PubMed: 21147995] [MGI Ref ID J:166739]
Dickey CA; Kamal A; Lundgren K; Klosak N; Bailey RM; Dunmore J; Ash P; Shoraka S; Zlatkovic J; Eckman CB; Patterson C; Dickson DW; Nahman NS Jr; Hutton M; Burrows F; Petrucelli L. 2007. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117(3):648-58. [PubMed: 17304350] [MGI Ref ID J:120752]
Ittner LM; Ke YD; Delerue F; Bi M; Gladbach A; van Eersel J; Wolfing H; Chieng BC; Christie MJ; Napier IA; Eckert A; Staufenbiel M; Hardeman E; Gotz J. 2010. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142(3):387-97. [PubMed: 20655099] [MGI Ref ID J:164597]
Keimpema E; Barabas K; Morozov YM; Tortoriello G; Torii M; Cameron G; Yanagawa Y; Watanabe M; Mackie K; Harkany T. 2010. Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. J Neurosci 30(42):13992-4007. [PubMed: 20962221] [MGI Ref ID J:165476]
Kelleher I; Garwood C; Hanger DP; Anderton BH; Noble W. 2007. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem 103(6):2256-67. [PubMed: 17908241] [MGI Ref ID J:128741]
Kickstein E; Krauss S; Thornhill P; Rutschow D; Zeller R; Sharkey J; Williamson R; Fuchs M; Kohler A; Glossmann H; Schneider R; Sutherland C; Schweiger S. 2010. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A :. [PubMed: 21098287] [MGI Ref ID J:167148]
Korets-Smith E; Lindemann L; Tucker KL; Jiang C; Kabacs N; Belteki G; Haigh J; Gertsenstein M; Nagy A. 2004. Cre recombinase specificity defined by the tau locus. Genesis 40(3):131-8. [PubMed: 15493019] [MGI Ref ID J:94203]
Leroy K; Ando K; Laporte V; Dedecker R; Suain V; Authelet M; Heraud C; Pierrot N; Yilmaz Z; Octave JN; Brion JP. 2012. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am J Pathol 181(6):1928-40. [PubMed: 23026200] [MGI Ref ID J:190305]
Levine S; Saltzman A; Levy E; Ginsberg SD. 2009. Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Exp Mol Pathol 86(1):18-22. [PubMed: 19041304] [MGI Ref ID J:174270]
Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Ronicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS. 2012. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 485(7400):651-5. [PubMed: 22660329] [MGI Ref ID J:186639]
Pacheco CD; Elrick MJ; Lieberman AP. 2009. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum Mol Genet 18(5):956-65. [PubMed: 19074461] [MGI Ref ID J:145003]
Phillips M; Boman E; Osterman H; Willhite D; Laska M. 2011. Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice-a longitudinal study. PLoS One 6(5):e19567. [PubMed: 21573167] [MGI Ref ID J:172426]
Polydoro M; Acker CM; Duff K; Castillo PE; Davies P. 2009. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29(34):10741-9. [PubMed: 19710325] [MGI Ref ID J:152310]
Tucker KL; Meyer M; Barde YA. 2001. Neurotrophins are required for nerve growth during development. Nat Neurosci 4(1):29-37. [PubMed: 11135642] [MGI Ref ID J:66561]
Willaredt MA; Hasenpusch-Theil K; Gardner HA; Kitanovic I; Hirschfeld-Warneken VC; Gojak CP; Gorgas K; Bradford CL; Spatz J; Wolfl S; Theil T; Tucker KL. 2008. A crucial role for primary cilia in cortical morphogenesis. J Neurosci 28(48):12887-900. [PubMed: 19036983] [MGI Ref ID J:142500]
Xiong Y; Jing XP; Zhou XW; Wang XL; Yang Y; Sun XY; Qiu M; Cao FY; Lu YM; Liu R; Wang JZ. 2013. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging 34(3):745-56. [PubMed: 22892311] [MGI Ref ID J:194513]
Yuan A; Kumar A; Peterhoff C; Duff K; Nixon RA. 2008. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 28(7):1682-7. [PubMed: 18272688] [MGI Ref ID J:132278]
Zaghetto AA; Paina S; Mantero S; Platonova N; Peretto P; Bovetti S; Puche A; Piccolo S; Merlo GR. 2007. Activation of the Wnt-beta catenin pathway in a cell population on the surface of the forebrain is essential for the establishment of olfactory axon connections. J Neurosci 27(36):9757-68. [PubMed: 17804636] [MGI Ref ID J:124891]
Andorfer C; Acker CM; Kress Y; Hof PR; Duff K; Davies P. 2005. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25(22):5446-54. [PubMed: 15930395] [MGI Ref ID J:98717]
Bhaskar K; Konerth M; Kokiko-Cochran ON; Cardona A; Ransohoff RM; Lamb BT. 2010. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68(1):19-31. [PubMed: 20920788] [MGI Ref ID J:167757]
Boutajangout A; Quartermain D; Sigurdsson EM. 2010. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49):16559-66. [PubMed: 21147995] [MGI Ref ID J:166739]
Dickey CA; Kamal A; Lundgren K; Klosak N; Bailey RM; Dunmore J; Ash P; Shoraka S; Zlatkovic J; Eckman CB; Patterson C; Dickson DW; Nahman NS Jr; Hutton M; Burrows F; Petrucelli L. 2007. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117(3):648-58. [PubMed: 17304350] [MGI Ref ID J:120752]
Duff K; Knight H; Refolo LM; Sanders S; Yu X; Picciano M; Malester B; Hutton M; Adamson J; Goedert M; Burki K; Davies P. 2000. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 7(2):87-98. [PubMed: 10783293] [MGI Ref ID J:85952]
Giliberto L; d'Abramo C; Acker CM; Davies P; D'Adamio L. 2010. Transgenic expression of the amyloid-beta precursor protein-intracellular domain does not induce Alzheimer's Disease-like traits in vivo. PLoS One 5(7):e11609. [PubMed: 20661273] [MGI Ref ID J:163095]
Kelleher I; Garwood C; Hanger DP; Anderton BH; Noble W. 2007. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem 103(6):2256-67. [PubMed: 17908241] [MGI Ref ID J:128741]
Kickstein E; Krauss S; Thornhill P; Rutschow D; Zeller R; Sharkey J; Williamson R; Fuchs M; Kohler A; Glossmann H; Schneider R; Sutherland C; Schweiger S. 2010. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A :. [PubMed: 21098287] [MGI Ref ID J:167148]
Levine S; Saltzman A; Levy E; Ginsberg SD. 2009. Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Exp Mol Pathol 86(1):18-22. [PubMed: 19041304] [MGI Ref ID J:174270]
Ma QL; Zuo X; Yang F; Ubeda OJ; Gant DJ; Alaverdyan M; Teng E; Hu S; Chen PP; Maiti P; Teter B; Cole GM; Frautschy SA. 2013. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 288(6):4056-65. [PubMed: 23264626] [MGI Ref ID J:195654]
Phillips M; Boman E; Osterman H; Willhite D; Laska M. 2011. Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice-a longitudinal study. PLoS One 6(5):e19567. [PubMed: 21573167] [MGI Ref ID J:172426]
Polydoro M; Acker CM; Duff K; Castillo PE; Davies P. 2009. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29(34):10741-9. [PubMed: 19710325] [MGI Ref ID J:152310]
Tucker KL; Meyer M; Barde YA. 2001. Neurotrophins are required for nerve growth during development. Nat Neurosci 4(1):29-37. [PubMed: 11135642] [MGI Ref ID J:66561]
Xiong Y; Jing XP; Zhou XW; Wang XL; Yang Y; Sun XY; Qiu M; Cao FY; Lu YM; Liu R; Wang JZ. 2013. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging 34(3):745-56. [PubMed: 22892311] [MGI Ref ID J:194513]
Yuan A; Kumar A; Peterhoff C; Duff K; Nixon RA. 2008. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 28(7):1682-7. [PubMed: 18272688] [MGI Ref ID J:132278]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number AX12
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, mice that are homozygous for the targeted mutation and hemizygous for the transgene are bred with mice homozygous for the targeted mutation and wildtype for the transgene. Mating System See Colony Maintenance under the Health & husbandry tab (Female x Male) 09-DEC-06 Diet Information LabDiet® 5K52/5K67
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Live Mice
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $232.00 Female or Male Homozygous for Mapttm1(EGFP)Klt, Hemizygous for Tg(MAPT)8cPdav $232.00 Female or Male Homozygous for Mapttm1(EGFP)Klt, Noncarrier
Price per Pair (US dollars $) Pair Genotype $464.00 Homozygous for Mapttm1(EGFP)Klt, Hemizygous for Tg(MAPT)8cPdav x Homozygous for Mapttm1(EGFP)Klt, Noncarrier $464.00 Homozygous for Mapttm1(EGFP)Klt, Noncarrier x Homozygous for Mapttm1(EGFP)Klt, Hemizygous for Tg(MAPT)8cPdav Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Pricing for International shipping destinations |
|
Live Mice
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $301.60 Female or Male Homozygous for Mapttm1(EGFP)Klt, Hemizygous for Tg(MAPT)8cPdav $301.60 Female or Male Homozygous for Mapttm1(EGFP)Klt, Noncarrier
Price per Pair (US dollars $) Pair Genotype $603.20 Homozygous for Mapttm1(EGFP)Klt, Hemizygous for Tg(MAPT)8cPdav x Homozygous for Mapttm1(EGFP)Klt, Noncarrier $603.20 Homozygous for Mapttm1(EGFP)Klt, Noncarrier x Homozygous for Mapttm1(EGFP)Klt, Hemizygous for Tg(MAPT)8cPdav Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
|
|
|
Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
General Supply Notes
- Genomic DNA is available for this strain from the Mouse DNA Resource.
Control Information
| Control | ||
|---|---|---|
| See control note: | Mice from the colony that are homozygous for the targeted mutation and noncarrier for the transgene should be considered for use as controls. The most appropriate control animal will depend on the nature of the experiment. | |
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.